These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24185588)

  • 1. Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
    Kumar SK; Mikhael J; Laplant B; Lacy MQ; Buadi FK; Dingli D; Gertz MA; Laumann K; Miceli T; Mahlman M; Bergsagel LP; Hayman SR; Reeder C; Stewart AK; Dispenzieri A; Gastineau DA; Winters JL
    Bone Marrow Transplant; 2014 Feb; 49(2):201-5. PubMed ID: 24185588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
    J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
    Malard F; Kröger N; Gabriel IH; Hübel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; Jaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):314-7. PubMed ID: 22001752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
    Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
    Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
    Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M
    Haematologica; 2024 May; 109(5):1525-1534. PubMed ID: 37981892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
    Micallef IN; Ho AD; Klein LM; Marulkar S; Gandhi PJ; Calandra G; McSweeney PA
    Bone Marrow Transplant; 2011 Mar; 46(3):350-5. PubMed ID: 20479709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
    Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
    Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
    Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
    Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
    Costa LJ; Abbas J; Hogan KR; Kramer C; McDonald K; Butcher CD; Littleton A; Shoptaw K; Kang Y; Stuart RK
    Bone Marrow Transplant; 2012 Nov; 47(11):1403-8. PubMed ID: 22484324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience.
    Thurlapati A; Roubal K; Davis JA; Shah SZ; Smith D; McGann M; Gaffney K; Cendagorta A; Maldonado A; Weeda E; Hashmi H
    Transplant Cell Ther; 2023 May; 29(5):340.e1-340.e4. PubMed ID: 36804934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
    Stewart DA; Smith C; MacFarland R; Calandra G
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
    Dugan MJ; Maziarz RT; Bensinger WI; Nademanee A; Liesveld J; Badel K; Dehner C; Gibney C; Bridger G; Calandra G
    Bone Marrow Transplant; 2010 Jan; 45(1):39-47. PubMed ID: 19483760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
    Yoshifuji K; Toya T; Adachi H; Fujita M; Wada A; Konuma R; Kishida Y; Konishi T; Nagata A; Yamada Y; Kaito S; Kumagai T; Inamoto K; Akiyama M; Igarashi A; Najima Y; Doki N; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
    Int J Hematol; 2019 Jul; 110(1):115-118. PubMed ID: 30989487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
    Costa LJ; Kramer C; Hogan KR; Butcher CD; Littleton AL; Shoptaw KB; Kang Y; Stuart RK
    Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial).
    Schmid A; Friess D; Mansouri Taleghani B; Keller P; Mueller BU; Baerlocher GM; Leibundgut K; Pabst T
    Leuk Lymphoma; 2015 Mar; 56(3):608-14. PubMed ID: 24884311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C; Waller EK
    Transfusion; 2015 Oct; 55(10):2351-7. PubMed ID: 26331348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
    Harvey RD; Kaufman JL; Johnson HR; Nooka A; Vaughn L; Flowers CR; Khoury HJ; Lechowicz MJ; Langston AA; Lonial S; Waller EK
    Biol Blood Marrow Transplant; 2013 Sep; 19(9):1393-5. PubMed ID: 23764455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.